STAT

3 China biotech stories to watch in 2019

In 2018, biotech in China generated relentless news. What's next for 2019?

As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here

This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

Вы читаете отрывок, зарегистрируйтесь, чтобы читать полное издание.

Другое от: STAT

STAT1 мин. чтенияBiology
STAT+: Pharmalittle: Pfizer-BioNTech Vaccine Seems To Work Against Covid-19 Mutation; Sarepta Gene Therapy Shows Mixed Results
United Kingdom regulators cleared the Moderna Covid-19 vaccine, adding a third shot for emergency use against the pandemic as infections surge there.
STAT1 мин. чтенияMedical
STAT+: Pharmalittle: Pfizer And BioNTech Say Vaccine Is Effective Against Covid-19 Variant; U.S. To Join COVAX Initiative
The Pfizer-BioNTech Covid-19 vaccine appears to work just as well against a fast-spreading variant first identified in the U.K. as it does against earlier forms of the coronavirus.
STAT1 мин. чтения
Sharon Begley, Path-breaking Science Journalist Who Spun Words Into Gold, Dies At 64
From the glory days of print magazines to 2020’s Twitter-crazed news cycles, Sharon Begley won more awards and accolades than could fit in an obituary. The accomplishments she was prouder…